Brief: Nektar Therapeutics Announces Research Collaboration With Ucsf And Dr. Stephen Hauser For Nktr-0165
17/02/2026 12:27
Feb 17 (Reuters) - Nektar Therapeutics NKTR.O: NEKTAR THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH UCSF AND DR. STEPHEN HAUSER FOR NKTR-0165, A TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) ANTIBODY, IN MULTIPLE SCLEROSIS Source text: ID:nPn63Px0Fa Further company coverage: NKTR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says